Stoke Therapeutics stock advances two clinical programs in October

Published on 10/08/2026 at 00:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stoke Therapeutics stock now has two dated clinical milestones after AAO presentations were announced on October 6, 2026. Q2 revenue reached USD 9.32 million.

STOK, US86150R1077, Illustration mit AI erstellt.

Stoke Therapeutics (ISIN US86150R1077) was last at USD 24.29 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, down 0.33 percent from the prior close. The company is advancing two clinical programs in October, with Stoke Therapeutics announcing two STK-002 presentations for the American Academy of Ophthalmology meeting on October 6, 2026.

Two programs reach clinical milestones

STK-002 is being tested in the Phase 1 OSPREY study for autosomal dominant optic atrophy. The first two dose cohorts are complete, while the third cohort is expected to finish by year-end 2026 and initial safety and efficacy data are anticipated in the first half of 2027, according to Stoke Therapeutics.

The second milestone concerns zorevunersen, Stoke's lead investigational medicine for Dravet syndrome. Following an FDA meeting dated October 5, 2026, the company said it plans a Phase 3 readout in the third quarter of 2027 and a U.S. NDA submission in the second half of 2027, as reported in the Stoke Therapeutics release.

Q2 revenue beat EPS expectations

The latest reported quarter ended June 30, 2026. Stoke posted revenue of USD 9.32 million, above the USD 4.89 million consensus estimate, while its loss of USD 0.93 per share was wider than the expected USD 0.80 loss, according to MarketBeat.

The contrast matters for the valuation story: revenue exceeded expectations by USD 4.43 million, but the adjusted EPS miss was USD 0.13 per share. MarketBeat listed a Moderate Buy consensus from 11 analysts, with an average price target of USD 44.25, including 10 Buy ratings and one Sell rating.

Stock remains below yearly high

At USD 24.29, STOK stood 39.6 percent below its 52-week high of USD 40.22 and above its 52-week low of USD 20.32 on October 7, 2026. Trading volume was 510,490 shares, while market capitalization was USD 1.6 billion on the same date.

The key investor tension is timing. The clinical milestones are dated for October 2026, year-end 2026 and the first half of 2027, while the central Phase 3 readout is expected in the third quarter of 2027. Stoke states that zorevunersen remains investigational and that its safety and efficacy have not been evaluated by a regulatory authority.

STOK heads toward its next report

EarningsToday lists November 3, 2026 as the scheduled date for Stoke's next report. The date places the next financial checkpoint before the company's later-stage clinical milestones.